Cibinetide (ARA-290) represents a significant advancement in therapeutic peptides, offering a unique approach to tissue protection and repair. This innovative synthetic 11-mer peptide is derived from the helix B surface domain of erythropoietin (EPO), meticulously engineered to mimic EPO's non-hematopoietic, tissue-protective functions without triggering unwanted erythropoietic activity.

The core of Cibinetide's therapeutic action lies in its selective binding to the Innate Repair Receptor (IRR). Unlike conventional EPO, which primarily interacts with a homodimeric EPO receptor to stimulate red blood cell production, Cibinetide targets the IRR – a heterodimer composed of the EPO receptor and the cytokine family beta common receptor (βCR, CD131). This targeted activation initiates a cascade of beneficial cellular responses, including potent anti-inflammatory effects, inhibition of cell death signals, and promotion of tissue regeneration. This mechanism makes Cibinetide particularly valuable, as it harnesses the body's intrinsic repair mechanisms while avoiding the hematological side effects associated with full-length EPO, such as increased blood viscosity and potential for thromboembolic events.

Clinical and preclinical studies have consistently demonstrated Cibinetide's broad therapeutic potential across a spectrum of conditions characterized by tissue injury and inflammation. It has shown remarkable efficacy in providing effective and long-term pain relief, particularly in cases of neuropathic pain resulting from peripheral nerve damage. This analgesic effect is mediated through its anti-inflammatory and immunomodulatory properties, integrating pain signaling with immune system responses.

Beyond pain management, Cibinetide exhibits significant promise as a neuroprotective agent. Research indicates its ability to improve corneal nerve fiber abundance in patients suffering from sarcoidosis-associated small nerve fiber loss, highlighting its role in nerve regeneration and repair. Furthermore, exploratory clinical trials have underscored its potential in treating serious ophthalmic conditions such as diabetic macular edema (DME), a leading cause of vision loss in people with diabetes. Its capacity to decrease retinal leakage and improve metabolic control makes it a compelling alternative or adjunct to existing, often invasive, treatments.

The versatility of Cibinetide extends to addressing inflammatory conditions like experimental colitis, where it has been shown to ameliorate disease course by dampening innate immune cell functions, reducing inflammatory cell infiltration, and inhibiting the production of pro-inflammatory mediators. Additionally, studies suggest its role in enhancing the proliferation, migration, and resistance to hydrogen peroxide-induced apoptosis of endothelial colony-forming cells, crucial for vascular health and repair. It also shows protective effects on isolated human islets in stressful environments, improving engraftment in the context of transplantation.

NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to being a premier manufacturer and supplier of high-quality Cibinetide (ARA-290) raw powder. Our commitment to stringent quality control ensures that our product meets the highest standards for research and pharmaceutical development. For those looking to buy or purchase Cibinetide, we offer competitive pricing and bulk quantities, establishing us as a reliable partner in the global market. Contact us today to learn more about our product specifications and current price lists. Our team is ready to assist with all your procurement needs, ensuring a seamless purchase experience for this advanced peptide.